WO2011131348A1 - Aliskiren in form of a solid dispersion - Google Patents

Aliskiren in form of a solid dispersion Download PDF

Info

Publication number
WO2011131348A1
WO2011131348A1 PCT/EP2011/001990 EP2011001990W WO2011131348A1 WO 2011131348 A1 WO2011131348 A1 WO 2011131348A1 EP 2011001990 W EP2011001990 W EP 2011001990W WO 2011131348 A1 WO2011131348 A1 WO 2011131348A1
Authority
WO
WIPO (PCT)
Prior art keywords
aliskiren
substrate
weight
base
aliskiren base
Prior art date
Application number
PCT/EP2011/001990
Other languages
French (fr)
Inventor
Ralph Stefan
Dominique Meergans
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Priority to CA2807374A priority Critical patent/CA2807374A1/en
Priority to EP11718287.3A priority patent/EP2590627A1/en
Publication of WO2011131348A1 publication Critical patent/WO2011131348A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the invention is related to an intermediate, containing Aliskiren as a free base and a substrate, the Aliskiren being present in form of a solid dispersion.
  • the invention further relates to methods of producing a solid dispersion of Aliskiren base and pharmaceutical formulations, especially tablets, containing Aliskiren base in form of a solid dispersion.
  • Aliskiren (IUPAC name: (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2-methyl-propyl)-4- hydroxy-7- ⁇ [4-methoxy-3-(3-methoxypropoxy)phenyl]methyl ⁇ -8-methyl-2-propane-2- yl-nonanamide) is reported to be a direct renin inhibitor.
  • Aliskiren is currently employed as a medicament for hypertension and is marketed by Novartis under the brand name TEKTURNA ® .
  • Aliskiren has the following chemical structure, formula (I):
  • the objective of the present invention was therefore to overcome the above-mentioned disadvantages.
  • the intention is to provide the active agent in a form possessing good flowability and allowing good compression into tablets. It is also the intention to provide the active agent in a form, which does not have a tendency to agglomerate. In addition, it is intended to enable an even distribution of the active agent. It is intended to avoid micronisation of the active agent in order to avoid the disadvantages usually associated with micronisation.
  • the intention is to provide Aliskiren in a form that makes it possible to achieve a high level of uniformity of the content (content uniformity), especially with a high content of active agent (drug load).
  • the intention is also to provide the active agent in a form, which possesses good solubility and good bioavailability with good storage stability at the same time.
  • the above objectives are achieved by providing Aliskiren in the form of a solid dispersion, with Aliskiren being used not as a pharmaceutically acceptable salt, but rather in the form of the free base.
  • the subject matter of the invention is therefore an intermediate, containing Aliskiren and substrate material, the Aliskiren being present in the form of a solid dispersion and preferably being used not as a pharmaceutically acceptable salt, but rather as a free base.
  • This intermediate of the invention is a solid dispersion of Aliskiren, especially Aliskiren base, in stabilised form.
  • the subject matter of the invention is also various methods of producing a solid dispersion of Aliskiren base in the form of the intermediate of the invention.
  • the subject matter of the invention also comprises pharmaceutical formulations containing the Aliskiren base of the invention in form of a solid dispersion or in form of the intermediate of the invention.
  • solid dispersion may be understood in the context of this invention as Aliskiren base being distributed on and/or in a substrate, which is preferably present in a solid aggregate state at 25 °C.
  • Aliskiren base can be distributed substantially homogeneously on and/or in the substrate.
  • This conventionally means that intermediates of this preferred embodiment exhibit a content uniformity with a standard deviation of ⁇ 6% (i.e. 94 % to 106 %).
  • An embodiment is particularly preferred which is characterised by a content uniformity with a standard deviation of ⁇ 3 % (i.e. 97 % to 103 %).
  • the "content uniformity" is determined in accordance with Ph. Eur. 6.0, section 2.9.6.
  • This intermediate of the invention is thus a solid dispersion of Aliskiren base in stabilised form.
  • Aliskiren base can be applied to and/or deposited in the substrate.
  • the expression “applied to” in this context means bound to the surface of the substrate by physicochemical interactions, such as van der Waals forces, hydrogen bonds, or charge transfer interactions.
  • the expression “deposited in” in this context means (at least partially) enclosed in the interior of the substrate structure by physico- chemical interactions, such as van der Waals forces, hydrogen bonds, or charge transfer interactions. It is preferable that at least 50 %, more preferably at least 70 %, even more preferably at least 90 %, especially at least 95 % of the substrate are wetted with Aliskiren base.
  • the Aliskiren base applied to the substrate and/or deposited in the substrate may be present in liquid or solid form. Aliskiren is preferably present in the intermediate of the invention in solid form.
  • solid dispersion may be understood in the context of this invention as Aliskiren base, stabilized on a solid support.
  • the term "substrate” may be understood in the context of this invention as material used as solid support. It is further preferred that the intermediate of the invention (containing Aliskiren base in the form of a solid dispersion) contains substantially no crystalline Aliskiren. In particular, the intermediate of the invention contains less than 15 % by weight, more preferably less than 5 % by weight, of crystalline Aliskiren base, based on the total weight of the Aliskiren base present in the intermediate.
  • the intermediate of the invention consists substantially of disperse Aliskiren base and substrate. If - as described below - a crystallisation inhibitor is used in addition, the intermediate of the invention may consist substantially of molecularly disperse Aliskiren base, substrate and crystallisation inhibitor. The word “substantially” in this case indicates that small amounts of solvent etc. may also be present where applicable.
  • the substrate is generally a substance which is capable of stabilising Aliskiren base in form of a solid dispersion, especially by acting as a support and/or enclosing it.
  • the substrate is preferably a polymer or an inorganic material.
  • the substrate also includes substances which behave like polymers.
  • the substrate is a substance, which can be non-water- soluble.
  • the non-water-soluble substrate is generally a pharmaceutical excipient specified in the European Pharmacopoeia which exhibits a water-solubility of less than 50 mg/1 , measured at 25 °C, more preferably of 25 mg/ml or less, even more preferably of 5 mg/ml or less, especially 0.01 to 4 mg/1.
  • Water-solubility is generally determined using the column elution method in accordance with EU Directive DIR 67-548 EEC, Annex V, Chap. A6.
  • the substrate can be a brittle substrate.
  • Pharmaceutical excipients for example substrates
  • the values for the "yield pressure” here are low for plastic substances but high in the case of friable substances on the other hand (Duberg, M., Nystrom, C, 1982, “Studies on direct compression of tablets VI. Evaluation of methods for the estimation of particle fragmentation during compaction.”, Acta Pharm. Suec. 19, 421-436; Humbert-Droz P., Mordier D., Doelker E., “Methodeless de determination du into a la compression pour des etudes de preformulation", Pharm. Acta Helv., 57, 136-143 (1982)).
  • the “yield pressure” describes the pressure that has to be reached for the excipient (i.e. preferably the substrate) to begin to flow plastically.
  • the "yield pressure” is preferably calculated using the reciprocal of the gradient of the Heckel plot, as described in York, P., Drug Dev. Ind. Pharm. 18, 677 (1992).
  • the meas- urement in this case is preferably made at 25 °C and a deformation rate of 0.1 mm s.
  • an excipient (especially a substrate) is deemed a non-brittle excipient if it has a "yield pressure" of no more than 120 MPa, preferably no more than 100 MPa, particularly preferably 5 to 80 MPa.
  • An excipient is usually de- scribed as a brittle excipient if it has a "yield pressure" of more than 80 MPa, preferably more than 100 MPa, particularly preferably more than 120 MPa, especially more than 150 MPa.
  • Brittle excipients may exhibit a "yield pressure" of up to 300 MPa or up to 400 MPa or even up to 500 MPa. Examples of non-brittle substrates are mannitol or starch.
  • brittle substrates are microcrystalline cellulose or calcium hydrogen phosphate, silicates or aluminosilicates.
  • fumed silica for example, Aerosil ® 200, or magnesium aluminosilicate, for example, Neusilin ® .
  • Neusilin ® can be represented by the empirical formula Al 2 0 3 MgOT .7SiCyxH 2 0.
  • a substrate more preferably a brittle substrate, for example fumed silica,
  • Brittle substrates are preferably used in the preparation of the intermediate of the invention.
  • the substrate is a swellable substrate.
  • the swellable substrate is preferably a swellable polymer or a swellable substance with polymer-like properties.
  • the swellable substrate preferably has a swelling index of 1.2 to 6.0, preferably 1.5 to 4.5, more preferably 2.0 to 4.0.
  • the swelling index indicates the volume in millilitres which 1 g substance, including any mucilage that may be adhering to it, occupies after swelling in an aqueous solution for 4 hours.
  • the swelling index is deter- mined in accordance with Ph. Eur. 4th edition, Chapter 2.8.4.
  • the substrate is a brittle and non-water-soluble or a brittle, non-water-soluble and swellable substrate.
  • the substrate used for the preparation of the intermediate of the invention may be a polymer which preferably has a glass transition temperature (Tg) higher than 20 °C, more preferably 25 °C, especially 35 °C.
  • Tg glass transition temperature
  • a polymer with an appropriately selected glass transition temperature causes immobilisation, which prevents the reversion of the Aliskiren base dispersion into larger, and hence no longer dispersely distributed particles.
  • glass transition temperature is used to describe the temperature at which amorphous or partially crystalline polymers change from the solid state to the liquid state. In the process, a distinct change in physical parameters, for example hardness and elasticity, occurs. Below the glass transition temperature, a polymer is usually glassy and hard, whereas above the glass transition temperature, it changes into a rubber-like to viscous state.
  • the glass transition temperature is determined in the context of this invention by means of dynamic differential scanning calorimetry (DSC). For this purpose a Mettler Toledo DSC 1 apparatus can be used. The work is performed at a heating rate of 1-20 °C/min, preferably 5-15° C/min, and at a cooling rate of 5- 25° C/min, preferably 10-20 °C/min.
  • the polymer to be used for the preparation of the intermediate preferably has a weight-average molecular weight of 1,000 to 500,000 g/mol, more preferably from 2,000 to 90,000 g/mol.
  • the weight-average molecular weight is preferably determined in the context of this application by means of gel permeation chromatography.
  • the resulting dispersion preferably has a viscosity of 0.1 to 18 mPaxs, more preferably 0.5 to 15 mPaxs, especially 1 to 8 mPaxs, measured at 25 °C and preferably determined in accordance with Ph. Eur. 6.0, Chapter 2.2.10.
  • Hydrophilic polymers are preferably used for the preparation of the intermediate. This means polymers which possess hydrophilic groups. Examples of suitable hydrophilic groups are hydroxy, alkoxy, acrylate, methacrylate, sulphonate, carboxylate and quaternary ammonium groups. Hydroxy groups are preferred.
  • the intermediate of the invention may, for example, comprise the following hydrophilic polymers as the substrate: polysaccharides, such as hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC, especially sodium and calcium salts), methyl cellulose, hydroxyethyl cellulose, ethyl hydroxyethyl cellulose, hydroxypropyl cellulose (HPC); microcrystalline cellulose, polyvinyl pyrrolidone, polyvinyl acetate (PVAC), polyvinyl alcohol (PVA), polymers of acrylic acid and their salts, polyacrylamide, polymethacrylates, vinyl pyrrolidone-vinyl acetate copolymers (such as Kollidon ® VA64, BASF), polyalkylene glycols, such as polypropylene glycol or preferably polyethylene glycol, co-block polymers of polyethylene glycol, especially co-block polymers of polyethylene glycol and polypropylene glycol (Pluronic ® , BASF), polyethylene
  • Preferable substances used as substrates are polyvinyl pyrrolidone, preferably with a weight-average molecular weight of 10,000 to 60,000 g/mol, especially 12,000 to 40,000 g/mol, a copolymer of vinyl pyrrolidone and vinyl acetate, especially with a weight-average molecular weight of 40,000 to 70,000 g/mol and/or polyethylene glycol, especially with a weight-average molecular weight of 2,000 to 10,000 g/mol, and HPMC, especially with a weight-average molecular weight of 20,000 to 90,000 g/mol and/or preferably a content of methyl groups of 10 to 35 % and a content of hydroxy groups of 1 to 35 %.
  • microcrystalline cellulose can preferably be used, especially one with a specific surface area of 0.7 - 1.4 m 2 /g. The specific surface area is determined by means of the gas adsorption method according to Brunauer, Emmet and Teller.
  • the substrate also includes solid, non-polymeric compounds which preferably contain polar side groups.
  • these are sugar alcohols or disaccharides.
  • suitable sugar alcohols and/or disaccharides are mannitol, sorbitol, xylitol, isomalt, glucose, fructose, maltose and mixtures thereof.
  • sugar alcohols in this context also includes monosaccharides.
  • cyclodextrins can be used, for example alpha-cyclodextrin, beta-cyclodextrin or gamma-cyclodextrin.
  • Silicates more preferably magnesium aluminosilicates and most preferably
  • Al 2 0 3 -Mg0 1.7Si0 2 -xH 2 0 are used as particularly preferred substrates.
  • the average particle diameter (D50) of the substrate particles being 1 to 250 ⁇ ⁇ ⁇ , preferably 10 to 200 ⁇ , more preferably 40 to 150 ⁇ .
  • the expression "average particle diameter” always relates in the context of this invention to the D50 value of the volume-average particle diameter determined by means of laser diffractometry.
  • a Malvern Instruments Mastersizer 2000 was used to determine the diameter (wet measurement with ultrasound for 60 sec, 2,000 rpm, the evaluation using the Fraunhofer method, and preferably using a dispersant in which the substance to be measured does not dissolve at 20 °C).
  • the average particle diameter which is also referred to as the D50 value of the integral volume distribution, is defined in the context of this invention as the particle diameter at which 50 % by volume of the particles have a smaller diameter than the diameter which corresponds to the D50 value. Similarly, 50 % by volume of the parti- cles then have a larger diameter than the D50 value.
  • the intermediate of the invention contains Aliskiren base and substrate, the weight ratio of Aliskiren base to substrate being 10 : 1 to 1 : 10, more preferably 5 : 1 to 1 : 5, especially 3 : 1 to 1 : 3.
  • the resulting intermediate has a glass transition temperature (Tg) of more than 20 °C, preferably more than 30 °C. Furthermore, the glass transition temperature of the intermediate should not be higher than 260 °C, preferably below 210 °C.
  • the intermediates of the invention can also contain a crystallisation inhibitor based on an inorganic salt, an organic acid or a high-molecular- weight polymer with an average molecular weight of more than 500,000 g/mol.
  • high-viscosity polymers which are suitable as crystallisation inhibitors, are also referred to in the context of this invention as "high-viscosity polymers". Their weight-average molecular weight is usually less than 5,000,000 g/mol. A preferred high-viscosity polymer is povidone.
  • the crystallisation inhibitor is preferably ammonium chloride, citric acid or Povidone K 90 (in accordance with Ph. Eur. 6.0).
  • the crystallisation inhibitor can generally be used in an amount of 0 to 30 % by weight, preferably 2 to 25 % by weight, more preferably 5 to 20 % by weight, based on the total weight of the intermediate.
  • the intermediates of the invention are obtainable by a variety of preparation methods. Depending on the preparation method, the intermediates are obtained in different particle sizes. Normally, the intermediates of the invention are present in particulate form and have an average particle diameter (D50) of 10 to 350 ⁇ , depending on the preparation method concerned.
  • the subject matter of the invention is also a method of preparing an intermediate containing Aliskiren and substrate, wherein Aliskiren base is present as a solid dispersion, comprising the steps of (a) dissolving Aliskiren base in a solvent or mixture of solvents, and con- tacting the solution with substrate,
  • step (c) optionally granulating the mixture obtained in step (b).
  • Aliskiren base is dissolved, preferably completely dissolved, in a solvent or mixture of solvents and contacted with the substrate.
  • the substrate described above is preferably likewise suspended or dissolved, preferably suspended, in this solvent or mixture of solvents (i.e. containing Aliskiren base).
  • the Aliskiren base and substrate are thus preferably contacted in a solvent or mixture of solvents. Where necessary, this can be done accompanied by stirring, for example for 1 minute to 1 hour.
  • Suitable solvents are, for example, water, alcohol (for example methanol, ethanol, isopropanol), dimethyl sulphoxide (DMSO), acetone, butanol, ethyl acetate, heptane, pentanol, chlorinated solvent (for example dichlormethane, chloroform) or mixtures thereof.
  • the solvent is ethanol or a mixture of water and alcohol, preferably ethanol, the weight ratio of alcohol : water being especially 50 : 50 to 99 : 1.
  • step (a) may also be arranged such that the Aliskiren base solution is applied to the substrate, such as by spraying.
  • the solvent or mixture of solvents is removed.
  • the removal of the mixture of solvents may, for example, be achieved by raising the temperature (for example 50 to 150 °C) and/or by reducing the pressure (for example 0.001 to 0.9 bar).
  • the solution, or preferably the suspension, from step (a) is spray-dried in step (b).
  • the spray-drying can be carried out in a spray tower.
  • a Biichi B-191 is suitable (Biichi Labortechnik GmbH, Germany).
  • an inlet temperature of 50 °C to 150 °C, more preferably 70 °C to 130 °C is chosen.
  • the amount of air is, for example, 500 to 700 litres/hour, and the aspirator preferably runs at 80 to 100 %.
  • the solution, or preferably the suspension, from step (a) is freeze-dried in step (b).
  • step (b) After the solvent has been removed, the mixture obtained in step (b) can be granulated, where applicable, in the optional step (c).
  • the granulation may preferably also take place during removal of the solvent, i.e. steps (b) and (c) may be performed simultaneously.
  • Steps (b) and (c) can preferably be performed in a fluidised bed granulator, such as a Glatt GPCG 3 (Glatt GmbH, Germany). Work is preferably performed with air inlet temperatures of 60 °C to 80 °C, with product temperatures of 30 °C to 40 °C and with a spray pressure of 1 to 1.5 bar.
  • a fluidised bed granulator such as a Glatt GPCG 3 (Glatt GmbH, Germany.
  • Work is preferably performed with air inlet temperatures of 60 °C to 80 °C, with product temperatures of 30 °C to 40 °C and with a spray pressure of 1 to 1.5 bar.
  • an Aliskiren base solution may be applied to (for example sprayed on) the substrate particles while they are located in the fluidised bed, i.e. steps (a), (b) and (c) may be performed simultaneously.
  • the intermediate of the invention i.e. Aliskiren base of the invention in the form of a solid dispersion
  • a pharmaceutical formulation i.e. Aliskiren base of the invention in the form of a solid dispersion
  • This is preferably a pharmaceutical formulation for oral administration, especially in the form of a tablet.
  • the subject matter of the invention is therefore a pharmaceutical formulation containing intermediate of the invention and pharmaceutical excipients.
  • pharmaceutical excipients These are the excipients with which the person skilled in the art is familiar, such as those, which are described in the European Pharmacopoeia.
  • excipients used are disintegrants, anti-sticking agents, emulsifiers, pseudo- emulsifiers, fillers, additives to improve the powder flowability, glidants, wetting agents and/or lubricants. Where appropriate, further excipients can also be used.
  • the ratio of active agent to excipients can preferably be selected such that the resulting formulations contain
  • the amount of substrate optionally used to prepare the interme- diate of the invention can be counted as an excipient.
  • the amount of active agent refers to the amount of Aliskiren base contained in the formulation.
  • the intermediates of the invention can be suitable for serving both as a basis for a dosage form with immediate release (or "IR” for short) and also with modified release (or “MR” for short) .
  • IR immediate release
  • MR modified release
  • the pharmaceutical formulation of the invention therefore can contain 5 to 30 % by weight, more preferably 10 to 25 % by weight, especially 12 to 22 % by weight disintegrant, based on the total weight of the formulation.
  • Disintegrants is the term generally used for substances, which accelerate the disintegration of a dosage form, especially a tablet, after it is placed in water.
  • Suitable disintegrants are, for example, organic disintegrants such as carrageenan, croscarmellose and crospovidone.
  • Alkaline disintegrants are likewise used.
  • alkaline disintegrants means disintegrants, which, when dissolved in water, produce a pH level of more than 7.0.
  • inorganic alkaline disintegrants are used, especially salts of alkali and alkaline earth metals.
  • Preferred examples here are sodium, potassium, magnesium and calcium.
  • carbonate and/or hydrogen carbonate are preferred.
  • Examples are sodium hydrogen carbonate, sodium hydrogen phosphate, calcium hydrogen carbonate and the like.
  • Sodium hydrogen carbonate can particularly preferably be used as a disintegrant, especially in the above-mentioned amounts.
  • the pharmaceutical formulation of the invention therefore can contain 0 to 10 % by weight, more preferably 0.1 to 5 % by weight, especially 1 to 4 % by weight disintegrant, based on the total weight of the formulation.
  • croscarmellose or crospovidone is preferred as the disintegrant.
  • the pharmaceutical formulation (both for IR and for MR) preferably contains one or more of the above-mentioned excipients. These will be explained in more detail below.
  • the formulation of the invention can contain 0 to 8 % by weight, more preferably 2 to 7 % by weight, especially 4 to 6 % by weight anti-sticking agent, based on the total weight of the formulation.
  • This embodiment can be used especially for the production of tablets.
  • Anti-sticking agents are usually understood to mean substances which reduce agglomeration in the core bed. Examples are talcum, silica gel, polyethylene glycol (preferably with 2,000 to 10,000 g/mol weight-average molecular weight) and/or glycerol mono alpha-cyclodextrin stearate.
  • the formulation of the invention can preferably contain fillers.
  • Fillers generally means substances, which serve, for example, to form the body of the tablet in the case of tablets with small amounts of active agent (for example less than 70 % by weight). This means that fillers "dilute" the active agents in order to produce an adequate tablet- compression mixture. The normal purpose of fillers, therefore, is to obtain a suitable tablet size.
  • Examples of preferred fillers are lactose, lactose derivatives, starch, starch derivatives, treated starch, talcum, calcium phosphate, dicalcium phosphate, sucrose, magnesium carbonate, magnesium oxide, maltodextrin, calcium sulphate, dextrates, dextrin, dex- trose, hydrogenated vegetable oil, kaolin, sodium chloride, and/or potassium chloride.
  • microcrystalline cellulose and/or siliconated microcrystalline cellulose for example obtainable as Prosolv ® Rettenmaier & Sonne, Germany
  • Fillers can generally be used in an amount of 0 to 60 % by weight, preferably 10 to 40 % by weight, especially 15 to 35 % by weight, based on the total weight of the formulation.
  • an additive to improve the powder flowability can be present in the pharmaceutical formulation.
  • One example of an additive to improve the powder flowability can be disperse silicon dioxide.
  • Additives to improve the powder flowability can be used in an amount of 0.1 to 3 % by weight, based on the total weight of the formulation.
  • Lubricants can be used in addition.
  • Lubricants are generally used to reduce sliding friction. In particular, the intention is to reduce the sliding friction found during tablet pressing between the punch moving up and down in the die and the die wall, on the one hand, and between the edge of the tablet and the die wall, on the other hand.
  • Suitable lubricants are, for example, stearic acid, adipic acid, sodium stearyl fumarate (Pruv ® ) and/or magnesium stearate.
  • Lubricants can generally be used in an amount of 0.1 to 3 % by weight, based on the total weight of the formulation.
  • the pharmaceutical formulation of the invention therefore can comprise
  • the pharmaceutical formulation of the invention may also contain one or more further active agents.
  • the pharmaceuti- cal formulation of the invention contains 0.1 to 10 % by weight, more preferably 0.5 to 8 % by weight of a further active agent, based on the total weight of the formulation.
  • the further active agent can be, for example, an ATI receptor antagonist, ACE inhibitor, beta blocker, calcium channel blocker, aldosterone synthase inhibitor, aldosterone receptor antagonist or preferably a diuretic. It is particularly preferably hydrochlorothi- azide (HCT, HCTZ or HCZ for short).
  • the pharmaceutical formulation of the invention can preferably be pressed into tablets.
  • the intermediates of the invention are therefore pressed into tablets by means of direct compression or are subjected to granulation, for example wet granulation or dry granulation, before being pressed into tablets.
  • Intermediates with a bulk density of less than 0.5 g/ml are preferably processed by dry granulation or wet granulation.
  • the tabletting conditions are preferably selected such that the resulting tablets have a ratio of tablet height to weight of 0.005 to 0.3 mm/mg, particularly preferably 0.05 to 0.2 mm/mg.
  • the resulting tablets preferably have a hardness of 50 to 200 N, particularly preferably 80 to 150 N.
  • the hardness is determined in accordance with Ph. Eur. 6.0, section 2.9.8.
  • the resulting tablets preferably have a friability of less than 5 %, particularly preferably less than 2 %, especially less than 1 %.
  • the friability is determined in accordance with Ph. Eur. 6.0, section 2.9.7.
  • the tablets of the invention usually have a "content uniformity" of 90 to 1 10 % of the average content, preferably 95 to 105 %, more preferably 98 to 102 %, especially 99 to 101 %.
  • the "content uniformity" is determined in accordance with Ph. Eur.6.0, section 2.9.6.
  • the release profile of the tablets of the invention according to the USP method (paddle, 0.1 n HC1, 75 rpm) after 10 minutes usually indicates a content released of at least 30 %, preferably at least 60 %, especially at least 80 %.
  • the release profile of the tablets of the invention ac- cording to the USP method (paddle, 0.1 n HC1, 75 rpm) after 60 minutes usually indi- cates a content released of not more than 20 %, preferably not more than 30 %, especially not more than 40 %. Within 8 hours, however, preferably at least 80 %, more preferably at least 90 %, has been released.
  • the above details regarding hardness, friability, content uniformity and release profile preferably relate here to the non-film-coated tablet for an IR formulation.
  • the release profile relates to the total formulation.
  • the tablets produced by the method of the invention may be tablets which can be swal- lowed unchewed (non-film-coated or preferably film-coated). They may likewise be chewable tablets or dispersible tablets. "Dispersible tablet” here means a tablet to be used for producing an aqueous suspension for swallowing.
  • macromolecular substances can preferably be used, such as modified celluloses, polymethacrylates, polyvinyl pyrrolidone, polyvinyl acetate phthalate, zein and/or shellack or natural gum, such as carrageenan.
  • the thickness of the coating is preferably 1 to 100 ⁇ , more preferably 5 to 60 ⁇ .
  • Possible dosage forms for the pharmaceutical formulations of the invention for oral administration include tablets, capsules, dispersions, suspensions and similar formulations. Tablets are preferred.
  • the dosage of the active agent or the combination of active agents may be varied, for example because of the nature of the disorder to be treated, the severity of the disorder and the dosage form.
  • the active agent Aliskiren contained is administered in a daily dose of 10 mg to 1,000 mg, preferably 50 mg to 600 mg, particularly preferably 75 mg to 300 mg and/or if the optionally contained active agent HCT is administered in a daily dose of 5 mg to 50 mg, preferably 10 mg to 25 mg.
  • the daily dose it is preferable for the daily dose to be administered once a day or for the daily dose to be administered spread over two to five doses. In the same doses, applications less than once a day are possible, such as every two, three or four days, for example in a delayed-release formulation.
  • the dosing regi- men may be varied within or even outside this frame in order to achieve the optimum treatment results.
  • the pharmaceutical formulations of the invention are usually characterised by a release and absorption that lead to advantageous figures for the AUC ("area under curve"), the area under the curve of the plasma level 0 to 48 hours after peroral administration), advantageous figures for the C max (maximum plasma level) and advantageous figures for the T max (time when the maximum plasma level is reached after peroral administration).
  • AUC area under curve
  • C max maximum plasma level
  • T max time when the maximum plasma level is reached after peroral administration
  • the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by a T max regarding the active agent Aliskiren of about 0.5 to 3 hours.
  • the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a T max regard- ing the active agent HCT of about 0.5 to 3 hours.
  • the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a C ma x regarding the active agent Aliskiren of about 10 to 90 ng/ml, preferably 20 to 80 ng/ml.
  • the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a C ma x regarding the active agent HCT of about 100 to 200 ng/ml, preferably 1 15 to 185 ng/ml.
  • the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by an AUC regarding the active agent Aliskiren of about 300 to 1,500 ngxh/ml, preferably 400 to 1,300 ngxh/ml.
  • the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by an AUC regarding the active agent HCT of about 500 to 1,500 ngxh/ml, preferably 650 to 1,350 ngxh/ml.
  • the above-mentioned plasma level figures are preferably average values, obtainable by examining blood samples from a group of 10 candidates (with an average body weight of 70 kg), the corresponding blood samples being taken 0, 1, 3, 4, 6, 8, 24 and 48 hours after the peroral administration of the formulation of the invention.
  • the plasma level figures can preferably be determined by means of appropriate HPLC-MSMS methods.
  • the AUC can be calculated by, for example, using a computer program such as the Microsoft Excel program.
  • the pharmaceutical formulations of the invention can be used to treat essential hypertension or cardiac insufficiency either as a mono-preparation or in combination with diuretics or ACE inhibitors. It is particularly preferable to treat patient groups in which the therapy with other antihypertensive agents, particularly preferably a monotherapy with diuretics or ACE inhibitors or a combined therapy of diuretics and ACE inhibitors, has not produced satisfactory results.
  • the subject matter of the invention is thus also a tablet containing 50 to 500 mg Aliskiren base and optionally 5 to 50 mg HCT, the tablet having a hardness of 50 to 250 N, a friability of less than 5 % and content uniformity of 95 to 105 %, and wherein the administration regarding the active agent Aliskiren leads to a T max of 0.5 to 3 hours, a C max of 10 to 90 ng/ml and an AUC of about 300 to 1,500 ngxh/ml, and wherein, where applicable, the administration regarding the active agent HCT leads to a T max of 0.5 to 3 hours, a C max of 100 to 200 ng/ml and an AUC of about 500 to 1 ,500 ngxh/ml.
  • Aliskiren is preferably present in the form of the intermediate of the invention.
  • the tablet of the invention accordingly preferably contains a pharmaceutical composition of the invention, especially in accordance with any of claims 10 to 14.
  • the administration of the tablet of the invention is preferably once a day.
  • Aliskiren base was dissolved with a sufficient quantity of ethanol 96 % and mixed with item 2. After sufficient agitating and subsequent drying, the dried cake was passed through a 0.8 mm screen and the screened (0.8 mm) items 4 - 6 were added. The mixture was mixed for 15 min in the Turbula ® . After that, item 7 was added via a screen (0.8 mm) and mixed for 15 min in the Turbula ® . The finished mixture was pressed into tablets of 1 1 mm diameter each; hardness 90-120 N.
  • Example 2 Formulation example for Aliskiren free base in combination with
  • Aliskiren base was dissolved in EtOH (96%) in a weight ratio of 1 : 1.
  • Neusilin ® was granulated with the solution of Aliskiren and EtOH in a high shear mixer (Diosna Pl/6) at 200 rpm mixer speed. After drying in a cabinet dryer at 40 °C for 12 h, the granules were sieved (mesh size 1.0 mm) and mixed with the sieved (mesh size 1.0 mm) Di Cafos ® AN, HCT, Aerosil ® 200 and Kollidon ® CL in a tumble blender (Turbula ® TB 10) for 15 min. Magnesium stearate was added through a sieve (mesh size 0.5 mm) and mixed to the final blend for a further 5 min.
  • the mixture was compressed to tablets of 1 1 mm diameter and a hardness of 170 N on a Riva Picola ® rotary press.
  • Example 3 Formulation example for Aliskiren free base in combination with
  • the mixture was pressed into oblong tablets 18 x 8.5 mm, using a rotary tabletting press (Riva), with 50-120 N hardness.
  • Example 1 The in vitro release of the tablets of Example 1, Example 2 and the comparative example was investigated (USP Method II, paddle, 500 ml 0.1 N HC1, pH 1.1, 37 °C, 75 rpm).
  • the tablets according to the present application show a superior dissolution profile in comparison to the prior art tablets.
  • the tablets according the present application were manufactured without the need of a salt-forming step of Aliskiren free base with an acid (for example for the preparation of Aliskiren hemifumarate). Further, the method according to the application avoids melt extrusion and therewith the accompanying high temperatures causing possible degradation of the heat- sensitive Aliskiren.
  • Another advantage of the this invention is the higher drug load of the pharmaceutical composition that can be achieved using the substrate of the present invention, preferably magnesium aluminosilicate, as compared to the polymers used in a melt extrusion process.

Abstract

The invention relates to an intermediate, containing Aliskiren and substrate, wherein the Aliskiren is present in the form of a solid dispersion. The invention further relates to methods of producing a solid dispersion of Aliskiren base and pharmaceutical formulations containing Aliskiren in the form of a solid dispersion.

Description

Aliskiren in Form of a Solid Dispersion
Background
The invention is related to an intermediate, containing Aliskiren as a free base and a substrate, the Aliskiren being present in form of a solid dispersion. The invention further relates to methods of producing a solid dispersion of Aliskiren base and pharmaceutical formulations, especially tablets, containing Aliskiren base in form of a solid dispersion.
Aliskiren (IUPAC name: (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2-methyl-propyl)-4- hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-propane-2- yl-nonanamide) is reported to be a direct renin inhibitor. Aliskiren is currently employed as a medicament for hypertension and is marketed by Novartis under the brand name TEKTURNA®. Aliskiren has the following chemical structure, formula (I):
Figure imgf000002_0001
formula (I)
A method of synthesising Aliskiren in form of the hemifumarate salt is described in EP 0 678 503 Al . It has, however, become clear that Aliskiren, especially in the form of the hemifumarate salt, is difficult to formulate, because crystalline Aliskiren is hygroscopic, amongst other properties, and exhibits poor flowability, cf. WO 2005/089729 Al . For this reason, amorphous Aliskiren has also been proposed in WO 2009/64479 Al . One problem in this context, however, is that the stability, compared to the crystalline state, is disadvantageous (cf. WO 2005/089729 Al, p. 2).
The objective of the present invention was therefore to overcome the above-mentioned disadvantages. The intention is to provide the active agent in a form possessing good flowability and allowing good compression into tablets. It is also the intention to provide the active agent in a form, which does not have a tendency to agglomerate. In addition, it is intended to enable an even distribution of the active agent. It is intended to avoid micronisation of the active agent in order to avoid the disadvantages usually associated with micronisation.
In addition, the intention is to provide Aliskiren in a form that makes it possible to achieve a high level of uniformity of the content (content uniformity), especially with a high content of active agent (drug load).
While developing Aliskiren formulations, the inventors of the present application were also confronted with the fact that crystalline Aliskiren hemifumarate - as described in WO 2009/064479 - can exist in different polymorphic forms. The different polymorphs are not stable, however, but have a tendency to convert into other polymorphs, for example under the influence of heat or in a moist environment. Moreover, the different polymorphic forms have different dissolution profiles. In a patient, the different dissolution profile leads to an undesirable, uneven rise in the concentration of the active agent. It was therefore an objective of the present invention to provide Aliskiren in a form enabling as even a rise as possible in the concentration in the patient. The aim was to avoid both inter-individual and also intra-individual deviations to a great extent.
The intention is also to provide the active agent in a form, which possesses good solubility and good bioavailability with good storage stability at the same time.
Summary of the invention
According to the invention, the above objectives are achieved by providing Aliskiren in the form of a solid dispersion, with Aliskiren being used not as a pharmaceutically acceptable salt, but rather in the form of the free base. The subject matter of the invention is therefore an intermediate, containing Aliskiren and substrate material, the Aliskiren being present in the form of a solid dispersion and preferably being used not as a pharmaceutically acceptable salt, but rather as a free base. This intermediate of the invention is a solid dispersion of Aliskiren, especially Aliskiren base, in stabilised form.
The subject matter of the invention is also various methods of producing a solid dispersion of Aliskiren base in the form of the intermediate of the invention.
Finally, the subject matter of the invention also comprises pharmaceutical formulations containing the Aliskiren base of the invention in form of a solid dispersion or in form of the intermediate of the invention.
Detailed description of the invention The term "solid dispersion" may be understood in the context of this invention as Aliskiren base being distributed on and/or in a substrate, which is preferably present in a solid aggregate state at 25 °C.
In a preferred embodiment, Aliskiren base can be distributed substantially homogeneously on and/or in the substrate. This conventionally means that intermediates of this preferred embodiment exhibit a content uniformity with a standard deviation of < 6% (i.e. 94 % to 106 %). An embodiment is particularly preferred which is characterised by a content uniformity with a standard deviation of < 3 % (i.e. 97 % to 103 %). The "content uniformity" is determined in accordance with Ph. Eur. 6.0, section 2.9.6.
This intermediate of the invention is thus a solid dispersion of Aliskiren base in stabilised form. In the intermediate of the invention, Aliskiren base can be applied to and/or deposited in the substrate. The expression "applied to" in this context means bound to the surface of the substrate by physicochemical interactions, such as van der Waals forces, hydrogen bonds, or charge transfer interactions. The expression "deposited in" in this context means (at least partially) enclosed in the interior of the substrate structure by physico- chemical interactions, such as van der Waals forces, hydrogen bonds, or charge transfer interactions. It is preferable that at least 50 %, more preferably at least 70 %, even more preferably at least 90 %, especially at least 95 % of the substrate are wetted with Aliskiren base. The Aliskiren base applied to the substrate and/or deposited in the substrate may be present in liquid or solid form. Aliskiren is preferably present in the intermediate of the invention in solid form.
Alternatively, the term "solid dispersion" may be understood in the context of this invention as Aliskiren base, stabilized on a solid support.
Also alternatively the term "substrate" may be understood in the context of this invention as material used as solid support. It is further preferred that the intermediate of the invention (containing Aliskiren base in the form of a solid dispersion) contains substantially no crystalline Aliskiren. In particular, the intermediate of the invention contains less than 15 % by weight, more preferably less than 5 % by weight, of crystalline Aliskiren base, based on the total weight of the Aliskiren base present in the intermediate.
In particular, the intermediate of the invention consists substantially of disperse Aliskiren base and substrate. If - as described below - a crystallisation inhibitor is used in addition, the intermediate of the invention may consist substantially of molecularly disperse Aliskiren base, substrate and crystallisation inhibitor. The word "substantially" in this case indicates that small amounts of solvent etc. may also be present where applicable.
The substrate is generally a substance which is capable of stabilising Aliskiren base in form of a solid dispersion, especially by acting as a support and/or enclosing it. The substrate is preferably a polymer or an inorganic material. In addition, the substrate also includes substances which behave like polymers.
In a preferred embodiment, the substrate is a substance, which can be non-water- soluble. The non-water-soluble substrate is generally a pharmaceutical excipient specified in the European Pharmacopoeia which exhibits a water-solubility of less than 50 mg/1 , measured at 25 °C, more preferably of 25 mg/ml or less, even more preferably of 5 mg/ml or less, especially 0.01 to 4 mg/1. Water-solubility is generally determined using the column elution method in accordance with EU Directive DIR 67-548 EEC, Annex V, Chap. A6.
In a further preferred embodiment, the substrate can be a brittle substrate. Pharmaceutical excipients (for example substrates) can generally be classified with regard to the change in the shape of the particles under compression pressure (compaction): plastic excipients are characterised by plastic deformation, whereas when compressive force is exerted on brittle excipients, the particles tend to break into smaller particles. Brittle behaviour on the part of the substrate can be quantified by the increase in the surface area in a moulding. In the art, it is customary to classify the brittleness in terms of the "yield pressure". According to a simple classification, the values for the "yield pressure" here are low for plastic substances but high in the case of friable substances on the other hand (Duberg, M., Nystrom, C, 1982, "Studies on direct compression of tablets VI. Evaluation of methods for the estimation of particle fragmentation during compaction.", Acta Pharm. Suec. 19, 421-436; Humbert-Droz P., Mordier D., Doelker E., "Methode rapide de determination du comportement a la compression pour des etudes de preformulation", Pharm. Acta Helv., 57, 136-143 (1982)). The "yield pressure" describes the pressure that has to be reached for the excipient (i.e. preferably the substrate) to begin to flow plastically.
The "yield pressure" is preferably calculated using the reciprocal of the gradient of the Heckel plot, as described in York, P., Drug Dev. Ind. Pharm. 18, 677 (1992). The meas- urement in this case is preferably made at 25 °C and a deformation rate of 0.1 mm s.
In the context of the present invention, an excipient (especially a substrate) is deemed a non-brittle excipient if it has a "yield pressure" of no more than 120 MPa, preferably no more than 100 MPa, particularly preferably 5 to 80 MPa. An excipient is usually de- scribed as a brittle excipient if it has a "yield pressure" of more than 80 MPa, preferably more than 100 MPa, particularly preferably more than 120 MPa, especially more than 150 MPa. Brittle excipients may exhibit a "yield pressure" of up to 300 MPa or up to 400 MPa or even up to 500 MPa. Examples of non-brittle substrates are mannitol or starch.
Examples of brittle substrates are microcrystalline cellulose or calcium hydrogen phosphate, silicates or aluminosilicates. Especially preferred are fumed silica, for example, Aerosil® 200, or magnesium aluminosilicate, for example, Neusilin®. Neusilin® can be represented by the empirical formula Al203 MgOT .7SiCyxH20. Preferably, a substrate, more preferably a brittle substrate, for example fumed silica,
2 2
with a specific surface of 50 to 400 m /g, more preferably 150-250 m /g, is used, wherein the specific surface is preferably determined by gas adsorption according Ph.Eur., 6th edition, chapter 2.9.26.
Brittle substrates are preferably used in the preparation of the intermediate of the invention.
In a further preferred embodiment, the substrate is a swellable substrate. The swellable substrate is preferably a swellable polymer or a swellable substance with polymer-like properties. The swellable substrate preferably has a swelling index of 1.2 to 6.0, preferably 1.5 to 4.5, more preferably 2.0 to 4.0. The swelling index indicates the volume in millilitres which 1 g substance, including any mucilage that may be adhering to it, occupies after swelling in an aqueous solution for 4 hours. The swelling index is deter- mined in accordance with Ph. Eur. 4th edition, Chapter 2.8.4.
It is especially preferred that the substrate is a brittle and non-water-soluble or a brittle, non-water-soluble and swellable substrate. In addition, the substrate used for the preparation of the intermediate of the invention may be a polymer which preferably has a glass transition temperature (Tg) higher than 20 °C, more preferably 25 °C, especially 35 °C. A polymer with an appropriately selected glass transition temperature causes immobilisation, which prevents the reversion of the Aliskiren base dispersion into larger, and hence no longer dispersely distributed particles.
The term "glass transition temperature" (Tg) is used to describe the temperature at which amorphous or partially crystalline polymers change from the solid state to the liquid state. In the process, a distinct change in physical parameters, for example hardness and elasticity, occurs. Below the glass transition temperature, a polymer is usually glassy and hard, whereas above the glass transition temperature, it changes into a rubber-like to viscous state. The glass transition temperature is determined in the context of this invention by means of dynamic differential scanning calorimetry (DSC). For this purpose a Mettler Toledo DSC 1 apparatus can be used. The work is performed at a heating rate of 1-20 °C/min, preferably 5-15° C/min, and at a cooling rate of 5- 25° C/min, preferably 10-20 °C/min.
In addition, the polymer to be used for the preparation of the intermediate preferably has a weight-average molecular weight of 1,000 to 500,000 g/mol, more preferably from 2,000 to 90,000 g/mol. The weight-average molecular weight is preferably determined in the context of this application by means of gel permeation chromatography. When the polymer used in the preparation of the intermediate is dissolved in water in an amount of 2 % by weight, the resulting dispersion preferably has a viscosity of 0.1 to 18 mPaxs, more preferably 0.5 to 15 mPaxs, especially 1 to 8 mPaxs, measured at 25 °C and preferably determined in accordance with Ph. Eur. 6.0, Chapter 2.2.10.
Hydrophilic polymers are preferably used for the preparation of the intermediate. This means polymers which possess hydrophilic groups. Examples of suitable hydrophilic groups are hydroxy, alkoxy, acrylate, methacrylate, sulphonate, carboxylate and quaternary ammonium groups. Hydroxy groups are preferred.
The intermediate of the invention may, for example, comprise the following hydrophilic polymers as the substrate: polysaccharides, such as hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC, especially sodium and calcium salts), methyl cellulose, hydroxyethyl cellulose, ethyl hydroxyethyl cellulose, hydroxypropyl cellulose (HPC); microcrystalline cellulose, polyvinyl pyrrolidone, polyvinyl acetate (PVAC), polyvinyl alcohol (PVA), polymers of acrylic acid and their salts, polyacrylamide, polymethacrylates, vinyl pyrrolidone-vinyl acetate copolymers (such as Kollidon® VA64, BASF), polyalkylene glycols, such as polypropylene glycol or preferably polyethylene glycol, co-block polymers of polyethylene glycol, especially co-block polymers of polyethylene glycol and polypropylene glycol (Pluronic®, BASF), polyethylene oxide and mixtures of the polymers mentioned. Preferable substances used as substrates are polyvinyl pyrrolidone, preferably with a weight-average molecular weight of 10,000 to 60,000 g/mol, especially 12,000 to 40,000 g/mol, a copolymer of vinyl pyrrolidone and vinyl acetate, especially with a weight-average molecular weight of 40,000 to 70,000 g/mol and/or polyethylene glycol, especially with a weight-average molecular weight of 2,000 to 10,000 g/mol, and HPMC, especially with a weight-average molecular weight of 20,000 to 90,000 g/mol and/or preferably a content of methyl groups of 10 to 35 % and a content of hydroxy groups of 1 to 35 %. In addition microcrystalline cellulose can preferably be used, especially one with a specific surface area of 0.7 - 1.4 m2/g. The specific surface area is determined by means of the gas adsorption method according to Brunauer, Emmet and Teller.
Furthermore, the substrate also includes solid, non-polymeric compounds which preferably contain polar side groups. Examples of these are sugar alcohols or disaccharides. Examples of suitable sugar alcohols and/or disaccharides are mannitol, sorbitol, xylitol, isomalt, glucose, fructose, maltose and mixtures thereof. The term "sugar alcohols" in this context also includes monosaccharides. In an alternative embodiment, cyclodextrins can be used, for example alpha-cyclodextrin, beta-cyclodextrin or gamma-cyclodextrin.
In principle, all mixtures of the substrates mentioned are also possible.
Silicates, more preferably magnesium aluminosilicates and most preferably
Al203-Mg0 1.7Si02-xH20, are used as particularly preferred substrates.
It is advantageous for the substrate to be used in particulate form, the average particle diameter (D50) of the substrate particles being 1 to 250 μηι, preferably 10 to 200 μιη, more preferably 40 to 150 μη . The expression "average particle diameter" always relates in the context of this invention to the D50 value of the volume-average particle diameter determined by means of laser diffractometry. In particular, a Malvern Instruments Mastersizer 2000 was used to determine the diameter (wet measurement with ultrasound for 60 sec, 2,000 rpm, the evaluation using the Fraunhofer method, and preferably using a dispersant in which the substance to be measured does not dissolve at 20 °C). The average particle diameter, which is also referred to as the D50 value of the integral volume distribution, is defined in the context of this invention as the particle diameter at which 50 % by volume of the particles have a smaller diameter than the diameter which corresponds to the D50 value. Similarly, 50 % by volume of the parti- cles then have a larger diameter than the D50 value.
In a preferred embodiment, the intermediate of the invention contains Aliskiren base and substrate, the weight ratio of Aliskiren base to substrate being 10 : 1 to 1 : 10, more preferably 5 : 1 to 1 : 5, especially 3 : 1 to 1 : 3.
It is preferable that that type and quantity of the substrate and the quantity of the Aliskiren base should be selected such that the resulting intermediate has a glass transition temperature (Tg) of more than 20 °C, preferably more than 30 °C. Furthermore, the glass transition temperature of the intermediate should not be higher than 260 °C, preferably below 210 °C.
In a preferred embodiment, in addition to Aliskiren base and substrate, the intermediates of the invention can also contain a crystallisation inhibitor based on an inorganic salt, an organic acid or a high-molecular- weight polymer with an average molecular weight of more than 500,000 g/mol.
These polymers, which are suitable as crystallisation inhibitors, are also referred to in the context of this invention as "high-viscosity polymers". Their weight-average molecular weight is usually less than 5,000,000 g/mol. A preferred high-viscosity polymer is povidone.
The crystallisation inhibitor is preferably ammonium chloride, citric acid or Povidone K 90 (in accordance with Ph. Eur. 6.0).
The crystallisation inhibitor can generally be used in an amount of 0 to 30 % by weight, preferably 2 to 25 % by weight, more preferably 5 to 20 % by weight, based on the total weight of the intermediate. The intermediates of the invention are obtainable by a variety of preparation methods. Depending on the preparation method, the intermediates are obtained in different particle sizes. Normally, the intermediates of the invention are present in particulate form and have an average particle diameter (D50) of 10 to 350 μηι, depending on the preparation method concerned.
The subject matter of the invention is also a method of preparing an intermediate containing Aliskiren and substrate, wherein Aliskiren base is present as a solid dispersion, comprising the steps of (a) dissolving Aliskiren base in a solvent or mixture of solvents, and con- tacting the solution with substrate,
(b) removing the solvent or mixture of solvents,
(c) optionally granulating the mixture obtained in step (b). In step (a) Aliskiren base is dissolved, preferably completely dissolved, in a solvent or mixture of solvents and contacted with the substrate. The substrate described above is preferably likewise suspended or dissolved, preferably suspended, in this solvent or mixture of solvents (i.e. containing Aliskiren base). The Aliskiren base and substrate are thus preferably contacted in a solvent or mixture of solvents. Where necessary, this can be done accompanied by stirring, for example for 1 minute to 1 hour.
Suitable solvents are, for example, water, alcohol (for example methanol, ethanol, isopropanol), dimethyl sulphoxide (DMSO), acetone, butanol, ethyl acetate, heptane, pentanol, chlorinated solvent (for example dichlormethane, chloroform) or mixtures thereof. Preferably, the solvent is ethanol or a mixture of water and alcohol, preferably ethanol, the weight ratio of alcohol : water being especially 50 : 50 to 99 : 1.
In an alternative embodiment, step (a) may also be arranged such that the Aliskiren base solution is applied to the substrate, such as by spraying.
In the subsequent step (b), the solvent or mixture of solvents is removed. The removal of the mixture of solvents may, for example, be achieved by raising the temperature (for example 50 to 150 °C) and/or by reducing the pressure (for example 0.001 to 0.9 bar). In a preferred embodiment, the solution, or preferably the suspension, from step (a) is spray-dried in step (b). The spray-drying can be carried out in a spray tower. As an example, a Biichi B-191 is suitable (Biichi Labortechnik GmbH, Germany). Preferably an inlet temperature of 50 °C to 150 °C, more preferably 70 °C to 130 °C, is chosen. The amount of air is, for example, 500 to 700 litres/hour, and the aspirator preferably runs at 80 to 100 %. In an alternative embodiment, the solution, or preferably the suspension, from step (a) is freeze-dried in step (b).
After the solvent has been removed, the mixture obtained in step (b) can be granulated, where applicable, in the optional step (c). The granulation may preferably also take place during removal of the solvent, i.e. steps (b) and (c) may be performed simultaneously.
Steps (b) and (c) can preferably be performed in a fluidised bed granulator, such as a Glatt GPCG 3 (Glatt GmbH, Germany). Work is preferably performed with air inlet temperatures of 60 °C to 80 °C, with product temperatures of 30 °C to 40 °C and with a spray pressure of 1 to 1.5 bar.
In accordance with the above alternative embodiment, an Aliskiren base solution may be applied to (for example sprayed on) the substrate particles while they are located in the fluidised bed, i.e. steps (a), (b) and (c) may be performed simultaneously.
The intermediate of the invention (i.e. Aliskiren base of the invention in the form of a solid dispersion) can be employed to prepare a pharmaceutical formulation. This is preferably a pharmaceutical formulation for oral administration, especially in the form of a tablet.
The subject matter of the invention is therefore a pharmaceutical formulation containing intermediate of the invention and pharmaceutical excipients. These are the excipients with which the person skilled in the art is familiar, such as those, which are described in the European Pharmacopoeia.
Examples of excipients used are disintegrants, anti-sticking agents, emulsifiers, pseudo- emulsifiers, fillers, additives to improve the powder flowability, glidants, wetting agents and/or lubricants. Where appropriate, further excipients can also be used.
The ratio of active agent to excipients can preferably be selected such that the resulting formulations contain
10 to 90 % by weight, more preferably 20 to 70 % by weight, especially 35 to 55 % by weight Aliskiren base, and
10 to 90 % by weight, more preferably 30 to 80 % by weight, especially 45 to 65 % by weight pharmaceutically acceptable excipients.
In these ratios specified, the amount of substrate optionally used to prepare the interme- diate of the invention can be counted as an excipient. This means that the amount of active agent refers to the amount of Aliskiren base contained in the formulation.
It has been shown that the intermediates of the invention can be suitable for serving both as a basis for a dosage form with immediate release (or "IR" for short) and also with modified release (or "MR" for short) .In a preferred embodiment for an IR formulation, a relatively large amount of disintegrant can be used. In that preferred embodiment, the pharmaceutical formulation of the invention therefore can contain 5 to 30 % by weight, more preferably 10 to 25 % by weight, especially 12 to 22 % by weight disintegrant, based on the total weight of the formulation. "Disintegrants" is the term generally used for substances, which accelerate the disintegration of a dosage form, especially a tablet, after it is placed in water. Suitable disintegrants are, for example, organic disintegrants such as carrageenan, croscarmellose and crospovidone. Alkaline disintegrants are likewise used. The term "alkaline disintegrants" means disintegrants, which, when dissolved in water, produce a pH level of more than 7.0.
More preferably, inorganic alkaline disintegrants are used, especially salts of alkali and alkaline earth metals. Preferred examples here are sodium, potassium, magnesium and calcium. As anions, carbonate and/or hydrogen carbonate, for example, are preferred. Examples are sodium hydrogen carbonate, sodium hydrogen phosphate, calcium hydrogen carbonate and the like.
Sodium hydrogen carbonate can particularly preferably be used as a disintegrant, especially in the above-mentioned amounts.
In a preferred embodiment for an MR formulation, a relatively small amount of disintegrant is used. In that preferred embodiment, the pharmaceutical formulation of the invention therefore can contain 0 to 10 % by weight, more preferably 0.1 to 5 % by weight, especially 1 to 4 % by weight disintegrant, based on the total weight of the formulation.
In the case of the MR formulation, croscarmellose or crospovidone is preferred as the disintegrant.
In addition the conventional retardation techniques can be used for the MR formulation.
Furthermore, the pharmaceutical formulation (both for IR and for MR) preferably contains one or more of the above-mentioned excipients. These will be explained in more detail below.
In a preferred embodiment, the formulation of the invention can contain 0 to 8 % by weight, more preferably 2 to 7 % by weight, especially 4 to 6 % by weight anti-sticking agent, based on the total weight of the formulation. This embodiment can be used especially for the production of tablets. "Anti-sticking agents" are usually understood to mean substances which reduce agglomeration in the core bed. Examples are talcum, silica gel, polyethylene glycol (preferably with 2,000 to 10,000 g/mol weight-average molecular weight) and/or glycerol mono alpha-cyclodextrin stearate. The formulation of the invention can preferably contain fillers. "Fillers" generally means substances, which serve, for example, to form the body of the tablet in the case of tablets with small amounts of active agent (for example less than 70 % by weight). This means that fillers "dilute" the active agents in order to produce an adequate tablet- compression mixture. The normal purpose of fillers, therefore, is to obtain a suitable tablet size.
Examples of preferred fillers are lactose, lactose derivatives, starch, starch derivatives, treated starch, talcum, calcium phosphate, dicalcium phosphate, sucrose, magnesium carbonate, magnesium oxide, maltodextrin, calcium sulphate, dextrates, dextrin, dex- trose, hydrogenated vegetable oil, kaolin, sodium chloride, and/or potassium chloride. Similarly, microcrystalline cellulose and/or siliconated microcrystalline cellulose (for example obtainable as Prosolv® Rettenmaier & Sonne, Germany) can be used as a filler.
Fillers can generally be used in an amount of 0 to 60 % by weight, preferably 10 to 40 % by weight, especially 15 to 35 % by weight, based on the total weight of the formulation.
Further, an additive to improve the powder flowability can be present in the pharmaceutical formulation. One example of an additive to improve the powder flowability can be disperse silicon dioxide. Additives to improve the powder flowability can be used in an amount of 0.1 to 3 % by weight, based on the total weight of the formulation.
Lubricants can be used in addition. Lubricants are generally used to reduce sliding friction. In particular, the intention is to reduce the sliding friction found during tablet pressing between the punch moving up and down in the die and the die wall, on the one hand, and between the edge of the tablet and the die wall, on the other hand. Suitable lubricants are, for example, stearic acid, adipic acid, sodium stearyl fumarate (Pruv®) and/or magnesium stearate.
Lubricants can generally be used in an amount of 0.1 to 3 % by weight, based on the total weight of the formulation.
In a preferred embodiment, the pharmaceutical formulation of the invention therefore can comprise
(i) 50 to 95 % by weight intermediate of the invention, preferably 60 to 90 % by weight intermediate,
(ii) 5 to 25 % by weight, preferably 8 to 15 % by weight disintegrant, (iii) 0 to 50 % by weight, preferably 10 to 35 % by weight filler, based on the total weight of the formulation.
In addition, it is preferred that the pharmaceutical formulation of the invention may also contain one or more further active agents. In a preferred embodiment, the pharmaceuti- cal formulation of the invention contains 0.1 to 10 % by weight, more preferably 0.5 to 8 % by weight of a further active agent, based on the total weight of the formulation. The further active agent can be, for example, an ATI receptor antagonist, ACE inhibitor, beta blocker, calcium channel blocker, aldosterone synthase inhibitor, aldosterone receptor antagonist or preferably a diuretic. It is particularly preferably hydrochlorothi- azide (HCT, HCTZ or HCZ for short).
The pharmaceutical formulation of the invention can preferably be pressed into tablets. The intermediates of the invention are therefore pressed into tablets by means of direct compression or are subjected to granulation, for example wet granulation or dry granulation, before being pressed into tablets. Intermediates with a bulk density of less than 0.5 g/ml are preferably processed by dry granulation or wet granulation.
The tabletting conditions are preferably selected such that the resulting tablets have a ratio of tablet height to weight of 0.005 to 0.3 mm/mg, particularly preferably 0.05 to 0.2 mm/mg.
In addition, the resulting tablets preferably have a hardness of 50 to 200 N, particularly preferably 80 to 150 N. The hardness is determined in accordance with Ph. Eur. 6.0, section 2.9.8.
In addition, the resulting tablets preferably have a friability of less than 5 %, particularly preferably less than 2 %, especially less than 1 %. The friability is determined in accordance with Ph. Eur. 6.0, section 2.9.7. Finally, the tablets of the invention usually have a "content uniformity" of 90 to 1 10 % of the average content, preferably 95 to 105 %, more preferably 98 to 102 %, especially 99 to 101 %. The "content uniformity" is determined in accordance with Ph. Eur.6.0, section 2.9.6. In the case of an IR formulation, the release profile of the tablets of the invention according to the USP method (paddle, 0.1 n HC1, 75 rpm) after 10 minutes usually indicates a content released of at least 30 %, preferably at least 60 %, especially at least 80 %.
In the case of an MR formulation, the release profile of the tablets of the invention ac- cording to the USP method (paddle, 0.1 n HC1, 75 rpm) after 60 minutes usually indi- cates a content released of not more than 20 %, preferably not more than 30 %, especially not more than 40 %. Within 8 hours, however, preferably at least 80 %, more preferably at least 90 %, has been released. The above details regarding hardness, friability, content uniformity and release profile preferably relate here to the non-film-coated tablet for an IR formulation. For a modi- fied-release tablet, the release profile relates to the total formulation.
The tablets produced by the method of the invention may be tablets which can be swal- lowed unchewed (non-film-coated or preferably film-coated). They may likewise be chewable tablets or dispersible tablets. "Dispersible tablet" here means a tablet to be used for producing an aqueous suspension for swallowing.
In the case of tablets which are swallowed unchewed, it is preferable that they are coat- ed with a film layer. For this purpose, the methods of film-coating tablets, which are standard in the state of the art, may be employed. The above-mentioned ratios of active agent to excipient, however, relate to the uncoated tablet.
For film-coating, macromolecular substances can preferably be used, such as modified celluloses, polymethacrylates, polyvinyl pyrrolidone, polyvinyl acetate phthalate, zein and/or shellack or natural gum, such as carrageenan.
The thickness of the coating is preferably 1 to 100 μιτι, more preferably 5 to 60 μηι. Possible dosage forms for the pharmaceutical formulations of the invention for oral administration include tablets, capsules, dispersions, suspensions and similar formulations. Tablets are preferred. The dosage of the active agent or the combination of active agents may be varied, for example because of the nature of the disorder to be treated, the severity of the disorder and the dosage form.
In treating the diseases which are indicated for the active agent or the combination of active agents in the formulations of the invention, satisfactory results are usually obtained if the active agent Aliskiren contained is administered in a daily dose of 10 mg to 1,000 mg, preferably 50 mg to 600 mg, particularly preferably 75 mg to 300 mg and/or if the optionally contained active agent HCT is administered in a daily dose of 5 mg to 50 mg, preferably 10 mg to 25 mg. In addition, it is preferable for the daily dose to be administered once a day or for the daily dose to be administered spread over two to five doses. In the same doses, applications less than once a day are possible, such as every two, three or four days, for example in a delayed-release formulation. The dosing regi- men may be varied within or even outside this frame in order to achieve the optimum treatment results.
The pharmaceutical formulations of the invention are usually characterised by a release and absorption that lead to advantageous figures for the AUC ("area under curve"), the area under the curve of the plasma level 0 to 48 hours after peroral administration), advantageous figures for the Cmax (maximum plasma level) and advantageous figures for the Tmax (time when the maximum plasma level is reached after peroral administration).
In a preferred embodiment, the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by a Tmax regarding the active agent Aliskiren of about 0.5 to 3 hours.
In a preferred embodiment, the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a Tmax regard- ing the active agent HCT of about 0.5 to 3 hours.
In a preferred embodiment, the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a Cmax regarding the active agent Aliskiren of about 10 to 90 ng/ml, preferably 20 to 80 ng/ml. In a preferred embodiment, the peroral administration of the formulations of the invention to a human patient can lead to a plasma level profile characterised by a Cmax regarding the active agent HCT of about 100 to 200 ng/ml, preferably 1 15 to 185 ng/ml.
In a preferred embodiment, the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by an AUC regarding the active agent Aliskiren of about 300 to 1,500 ngxh/ml, preferably 400 to 1,300 ngxh/ml.
In a preferred embodiment, the peroral administration of the formulations of the inven- tion to a human patient can lead to a plasma level profile characterised by an AUC regarding the active agent HCT of about 500 to 1,500 ngxh/ml, preferably 650 to 1,350 ngxh/ml.
The above-mentioned plasma level figures are preferably average values, obtainable by examining blood samples from a group of 10 candidates (with an average body weight of 70 kg), the corresponding blood samples being taken 0, 1, 3, 4, 6, 8, 24 and 48 hours after the peroral administration of the formulation of the invention. The plasma level figures can preferably be determined by means of appropriate HPLC-MSMS methods. The AUC can be calculated by, for example, using a computer program such as the Microsoft Excel program. In a preferred embodiment, the pharmaceutical formulations of the invention can be used to treat essential hypertension or cardiac insufficiency either as a mono-preparation or in combination with diuretics or ACE inhibitors. It is particularly preferable to treat patient groups in which the therapy with other antihypertensive agents, particularly preferably a monotherapy with diuretics or ACE inhibitors or a combined therapy of diuretics and ACE inhibitors, has not produced satisfactory results.
The subject matter of the invention is thus also a tablet containing 50 to 500 mg Aliskiren base and optionally 5 to 50 mg HCT, the tablet having a hardness of 50 to 250 N, a friability of less than 5 % and content uniformity of 95 to 105 %, and wherein the administration regarding the active agent Aliskiren leads to a Tmax of 0.5 to 3 hours, a Cmax of 10 to 90 ng/ml and an AUC of about 300 to 1,500 ngxh/ml, and wherein, where applicable, the administration regarding the active agent HCT leads to a Tmax of 0.5 to 3 hours, a Cmax of 100 to 200 ng/ml and an AUC of about 500 to 1 ,500 ngxh/ml. In the tablet of the invention, Aliskiren is preferably present in the form of the intermediate of the invention. The tablet of the invention accordingly preferably contains a pharmaceutical composition of the invention, especially in accordance with any of claims 10 to 14. The administration of the tablet of the invention is preferably once a day.
The invention will now be illustrated with reference to the following examples.
EXAMPLES Example 1
1. Aliskiren base 150 mg
2. Microcrystalline cellulose 150 mg
3. EtOH 96 % q.s.
4. Microcrystalline cellulose 100 mg
5. Aerosil® 200 5 mg
6. Crospovidone 30 mg
7. Magnesium stearate 15 mg
Aliskiren base was dissolved with a sufficient quantity of ethanol 96 % and mixed with item 2. After sufficient agitating and subsequent drying, the dried cake was passed through a 0.8 mm screen and the screened (0.8 mm) items 4 - 6 were added. The mixture was mixed for 15 min in the Turbula®. After that, item 7 was added via a screen (0.8 mm) and mixed for 15 min in the Turbula®. The finished mixture was pressed into tablets of 1 1 mm diameter each; hardness 90-120 N.
Example 2: Formulation example for Aliskiren free base in combination with
HCT
1. Aliskiren base 300 mg
2. Hydrochlorothiazide (HCT) 12.5 mg
3. Neusilin® US2 130 mg
4. Di Cafos® AN 152.5 mg
5. Aerosil® 200 5 mg
6. Kollidon® CL 40 mg
7. Magnesium stearate 10 mg
8. EtOH 96% q.s.
Aliskiren base was dissolved in EtOH (96%) in a weight ratio of 1 : 1. Neusilin® was granulated with the solution of Aliskiren and EtOH in a high shear mixer (Diosna Pl/6) at 200 rpm mixer speed. After drying in a cabinet dryer at 40 °C for 12 h, the granules were sieved (mesh size 1.0 mm) and mixed with the sieved (mesh size 1.0 mm) Di Cafos® AN, HCT, Aerosil® 200 and Kollidon® CL in a tumble blender (Turbula® TB 10) for 15 min. Magnesium stearate was added through a sieve (mesh size 0.5 mm) and mixed to the final blend for a further 5 min.
The mixture was compressed to tablets of 1 1 mm diameter and a hardness of 170 N on a Riva Picola® rotary press.
Example 3: Formulation example for Aliskiren free base in combination with
HCT
1. Aliskiren base 300 mg
2. Di Cafos® AN 300 mg
3. Hydrochlorothiazide (HCT) 12.5 mg
4. Di Cafos® AN 20 mg
5. Di Cafos® AN 50 mg
6. Aerosil® 200 8 mg
7. Crospovidone 40 mg
8. Magnesium stearate 10 mg
9. EtOH 96 % q.s. Aliskiren base was dissolved in EtOH, and Di Cafos AN (item 2.) was mixed with that solution and dried. After drying, the mixture was passed through a screen (0.8 mm) and mixed with Di Cafos® AN (item 5.) for 10 min in the Turbula®. HCT and Di Cafos® AN (item 4.) were passed through a screen (0.8 mm) and mixed for 10 min in the Turbula®. The mixture was added to the dried and screened mixture from items 1., 2. and 5., Aero- sil® 200 and crospovidone were added via a screen and mixed for 10 min in the Turbula®. Magnesium stearate was added via a screen and mixed for 5 min.
The mixture was pressed into oblong tablets 18 x 8.5 mm, using a rotary tabletting press (Riva), with 50-120 N hardness.
Comparative Example:
Marketed prior art tablet (Tekturna HCT®). Example 4: In vitro release
The in vitro release of the tablets of Example 1, Example 2 and the comparative example was investigated (USP Method II, paddle, 500 ml 0.1 N HC1, pH 1.1, 37 °C, 75 rpm).
Table 1
Figure imgf000019_0001
As shown in Table 1, the tablets according to the present application show a superior dissolution profile in comparison to the prior art tablets.
Additionally, the tablets according the present application were manufactured without the need of a salt-forming step of Aliskiren free base with an acid (for example for the preparation of Aliskiren hemifumarate). Further, the method according to the application avoids melt extrusion and therewith the accompanying high temperatures causing possible degradation of the heat- sensitive Aliskiren. Another advantage of the this invention is the higher drug load of the pharmaceutical composition that can be achieved using the substrate of the present invention, preferably magnesium aluminosilicate, as compared to the polymers used in a melt extrusion process.

Claims

Claims
1. An intermediate, containing Aliskiren base and substrate, wherein Aliskiren base is present as a solid dispersion.
2. The intermediate as claimed in claim 1 , wherein Aliskiren base is applied to the substrate and/or deposited in the substrate.
3. The intermediate as claimed in either of claims 1 or 2, wherein the weight ratio of Aliskiren base to substrate is 10 : 1 to 1 : 10.
4. The intermediate as claimed in any of claims 1 to 3, wherein the substrate is a brittle substrate with a yield pressure of more than 80 MPa.
5. The intermediate as claimed in any of claims 1 to 4, wherein a non- water-soluble substrate is used.
6. The intermediate as claimed in any of claims 1 to 5, wherein a swellable substrate is used.
7. A method of preparing an intermediate containing Aliskiren and substrate, wherein Aliskiren base is present as a solid dispersion, comprising the steps of
(a) dissolving Aliskiren base in a solvent or mixture of solvents, and contacting the solution with a substrate,
(b) removing the solvent or mixture of solvents,
(c) optionally granulating the mixture obtained in step (b).
8. The method as claimed in claim 7, wherein step (b) is performed as a freeze- drying step or spray-drying step.
9. The method as claimed in claim 7, wherein steps (b) and (c) are performed in a fluidised-bed granulator.
10. An intermediate obtainable by a method as claimed in anyone of claims 7 to 9.
1 1. A pharmaceutical formulation containing Aliskiren base in the form of an intermediate as claimed in any of claims 1 to 6 and 10, and optionally at least one further pharmaceutical excipient.
12. The pharmaceutical formulation as claimed in claim 11 for oral administration, preferably in the form of a tablet.
13. The pharmaceutical formulation as claimed in either of claims 11 or 12, con- taining
(i) 50 to 95 % by weight intermediate,
(ii) 5 to 25 % by weight disintegrant,
(iii) 0 to 50 % by weight filler, based on the total weight of the formulation.
14. The pharmaceutical formulation as claimed in any of claims 1 1 to 13, containing 0.1 to 10 % by weight of a further active agent, preferably hydrochlorothiazide.
15. A tablet containing 50 to 500 mg Aliskiren base, wherein the tablet has a hardness of 50 to 250 N, a friability of less than 5 % and a content uniformity of 95 to 105 %, wherein the administration regarding the active agent Aliskiren leads to a Tmax of 0.5 to 3 hours, a Cmax of 10 to 90 ng/ml and an AUC of about 300 to 1,500 ngxh/ml, and wherein the administration is performed once to twice daily.
PCT/EP2011/001990 2010-04-21 2011-04-19 Aliskiren in form of a solid dispersion WO2011131348A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2807374A CA2807374A1 (en) 2010-04-21 2011-04-19 Aliskiren in form of a solid dispersion
EP11718287.3A EP2590627A1 (en) 2010-04-21 2011-04-19 Aliskiren in form of a solid dispersion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004251A EP2382967A1 (en) 2010-04-21 2010-04-21 Aliskiren in the form of a solid dispersion
EP10004251.4 2010-04-21

Publications (1)

Publication Number Publication Date
WO2011131348A1 true WO2011131348A1 (en) 2011-10-27

Family

ID=42711960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/001990 WO2011131348A1 (en) 2010-04-21 2011-04-19 Aliskiren in form of a solid dispersion

Country Status (3)

Country Link
EP (2) EP2382967A1 (en)
CA (1) CA2807374A1 (en)
WO (1) WO2011131348A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678503A1 (en) 1994-04-18 1995-10-25 Ciba-Geigy Ag Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities
WO2005089729A2 (en) 2004-03-17 2005-09-29 Novartis Ag Galenic formulations of organic compounds
WO2009064479A1 (en) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
WO2010036686A1 (en) * 2008-09-24 2010-04-01 Novartis Ag Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678503A1 (en) 1994-04-18 1995-10-25 Ciba-Geigy Ag Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities
WO2005089729A2 (en) 2004-03-17 2005-09-29 Novartis Ag Galenic formulations of organic compounds
WO2009064479A1 (en) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
WO2010036686A1 (en) * 2008-09-24 2010-04-01 Novartis Ag Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Ph.Eur."
DUBERG, M., NYSTR6M, C.: "Studies on direct compression of tablets VI. Evaluation of methods for the estimation of particle fragmentation during compaction", ACTA PHARM. SUEC., vol. 19, 1982, pages 421 - 436
HUMBERT-DROZ P., MORDIER D., DOELKER E.: "Méthode rapide de determination du comportement a la compression pour des etudes de preformulation", PHARM. ACTA HELV., vol. 57, 1982, pages 136 - 143
REPKA MICHAEL A ET AL: "Pharmaceutical applications of hot-melt extrusion: Part II", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US LNKD- DOI:10.1080/03639040701525627, vol. 33, no. 10, 1 October 2007 (2007-10-01), pages 1043 - 1057, XP009106810, ISSN: 0363-9045 *
See also references of EP2590627A1 *
YORK, P., DRUG DEV. IND. PHARM., vol. 18, 1992, pages 677

Also Published As

Publication number Publication date
EP2590627A1 (en) 2013-05-15
CA2807374A1 (en) 2011-10-27
EP2382967A1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
US20120046315A1 (en) Intermediate and oral administrative formats containing lenalidomide
JP4707073B2 (en) Particulate pharmaceutical composition for oral administration of atorvastatin
US20110300214A1 (en) Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
US20120053238A1 (en) Solid retigabine in non-crystalline form
EP2554159A1 (en) Dosage forms comprising apixaban and content uniformity enhancer
US20140319720A1 (en) Pharmaceutical compositions comprising rivaroxaban
TWI414295B (en) Pharmaceutical compositions with superior product performance and patient compliance
EP2620140A1 (en) Crizotinib containing compositions
CA2785684A1 (en) Melt-granulated cinacalcet
US20120122973A1 (en) Dry processing of retigabine
EP2524688B1 (en) Composition for modified release comprising ranolazine
US20130116333A1 (en) Solid tapentadol in non-crystalline form
EP2590627A1 (en) Aliskiren in form of a solid dispersion
CA2866203A1 (en) Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
WO2012016708A1 (en) Oral dosage form comprising dimebolin and donepezil
CA2866206A1 (en) Dosage form comprising lopinavir and ritonavir
EP2621472A1 (en) Dry processing of atazanavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718287

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2807374

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011718287

Country of ref document: EP